FAP and non-small cell lung carcinoma: Continued analysis was performed on subsets of NSCLC patients who received PD-1 blockade monotherapy, and an association of high FAP expression with shortened PFS was also observed (HR 4.28, 95% CI 2.22–8.28, p < 0.0001, Supplementary Fig. 4e).